Renal Failure最新文献

{"title":"Simple methods for estimating the maximum 24-hour urinary potassium excretion in kidney failure without replacement therapy patients.","authors":"Danyang Zhang, Yukun Wang, Shimin Jiang, Wenge Li","doi":"10.1080/0886022X.2024.2445157","DOIUrl":"10.1080/0886022X.2024.2445157","url":null,"abstract":"<p><strong>Background: </strong>Adjusting dietary potassium intake based on 24-hour urinary potassium excretion is the primary method of preventing hyperkalemia. Currently, there is no accurate and convenient method for calculating maximum 24-hour urinary potassium excretion in kidney failure without replacement therapy patients. We developed and validated two new models to assess the upper limit of dietary potassium consumption in this high-risk cohort, using the maximum 24-hour urinary potassium excretion as a proxy.</p><p><strong>Methods: </strong>The data of 145 kidney failure without replacement therapy patients with hyperkalemia was gathered. The prediction models were developed using multilayer perceptron and stepwise multiple linear regression utilizing a stochastic sample of 102 (70%) patients. Within the rest 43 (30%), the performance of various models was independently verified.</p><p><strong>Results: </strong>The two new models had low bias (-0.02 and -0.57 mmol/24h vs 66.74 and 79.91 mmol/24h, mean absolute error = 5.57 and 5.22 vs 68.95 and 81.37), high accuracy (percentage of calculated values within_±30% of measured values = 83.45% and 84.14% vs 0.00% and 0.00%), high correlation with measured values (Spearman correlation coefficient = 0.72 and 0.72 vs 0.46 and 0.45, intraclass correlation coefficient = 0.67 and 0.70 vs 0.03 and 0.03) and high agreement with 24-hour urine potassium measurements (95% limits of agreement of Bland-Altman plot = 13.70 and 13.20 mmol/24h vs 113.8 and 191.3 mmol/24h).</p><p><strong>Conclusion: </strong>These new models show high clinical application value for the calculation of maximum 24-hour urinary potassium excretion in kidney failure without replacement therapy patients with hyperkalemia.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2445157"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142953543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A hidden gem on the banks of the Danube River-our experience at the 28^th Budapest Nephrology School.","authors":"Joshua H Lipschutz, Mihály Tapolyai","doi":"10.1080/0886022X.2025.2453010","DOIUrl":"10.1080/0886022X.2025.2453010","url":null,"abstract":"","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2453010"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for IgA nephropathy recurrence and impact on graft survival in a cohort of kidney transplanted patients.","authors":"Angelodaniele Napoletano, Michele Provenzano, Federica Maritati, Valeria Corradetti, Vania Cuna, Elisa Gessaroli, Chiara Abenavoli, Simona Barbuto, Marcello Demetri, Matteo Ravaioli, Giorgia Comai, Gaetano La Manna","doi":"10.1080/0886022X.2025.2472041","DOIUrl":"10.1080/0886022X.2025.2472041","url":null,"abstract":"<p><p>Recurrence of IgA nephropathy (IgAN) after kidney transplant (KT) appears associated with worse graft survival; thus, the identification of risk factors is worthwhile to improve pre-transplant evaluation of KT recipients and to identify the optimal treatment strategy. The aim of this study was to determine incidence, risk factors and impact on renal function and graft survival of IgAN recurrence after KT. We performed a retrospective study including 110 patients with biopsy-proven IgAN, who underwent KT at Policlinico di Sant'Orsola Hospital - University of Bologna from 2005 to 2021. IgAN recurred in 14 patients (12.7%) with a median time-to-recurrence of 59 (16-90) months. We found that a faster progression from IgAN diagnosis to end-stage kidney disease (ESKD), a younger age at ESKD, and a younger age at KT were associated with a higher risk of recurrence. During the first 2 years after KT, 24 h proteinuria was higher in patients with IgAN recurrence than in patients without (0.40 (0.11-1.8) vs 0.22 (0.18-0.37) g/day, <i>p</i> = 0.0003). During the follow-up period, a more rapid decline in eGFR was observed in the Recurrence group (<i>p</i> = 0.023). Additionally, graft survival at 10 years post-kidney transplant was significantly lower in this group (log-rank test <i>p</i> = 0.015). In conclusion, we found that patients with a more aggressive form of IgAN, who reached ESKD before 36 years of age, had an higher risk of recurrence in KT. Moreover we confirmed that recurrent IgAN, especially if clinically relevant, is associated with a worse graft outcome.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2472041"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of refractory central venous occlusive disease treated by stent deployment in patients undergoing maintenance hemodialysis.","authors":"Yuqin Xiong, Yan Wang, Xiaoqin He, Yi Ruan, Yue Wen, Yang Yu, Ping Fu","doi":"10.1080/0886022X.2025.2463579","DOIUrl":"10.1080/0886022X.2025.2463579","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the long-term outcomes of stent deployment in the treatment of refractory central venous occlusive disease (CVOD) in patients undergoing maintenance hemodialysis (MHD).</p><p><strong>Methods: </strong>MHD patients who were successfully treated with stenting for symptomatic CVOD that was resistant to balloon angioplasty alone were consecutively included in this retrospective study. The primary (PPR) and assisted (APR) patency rates of the central vein and hemodialysis vascular access (VA), reintervention, and survival rates after stenting were followed. Multivariate logistic regression analyses were conducted to determine the factors influencing VA abandonment and mortality.</p><p><strong>Results: </strong>The cohort comprised 65 patients (52.3% male) aged 61.5 ± 13.5 years, with a mean dialysis vintage of 54.7 ± 39.1 months. During 40 (20-54) months of follow-up, symptomatic CVOD recurred in 32 (49.2%) patients, accounting for 51 secondary angioplasties, including 34 stenting procedures. The PPR and APR at 12, 24, 36, 48, and 60 months were 81%, 52%, 47%, 41%, and 41% and 98%, 98%, 82%, 82%, and 82%, respectively. VA abandonment was noted in 10 (15.4%) patients. Six (9.2%) and 17 (26.2%) patients died due to cardiovascular conditions and all causes, respectively. The number of secondary stenting procedures was significantly associated with decreased VA abandonment [odds ratio (OR) = 0.089, 95% confidence interval (CI): 0.008-0.992, <i>p</i> = 0.049] and all-cause mortality (OR = 0.104, 95% CI: 0.011-0.947, <i>p</i> = 0.045).</p><p><strong>Conclusions: </strong>Angioplasty with stenting is an effective and promising strategy for MHD patients with refractory CVOD.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2463579"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and validation of a fall risk prediction model in elderly maintenance hemodialysis patients: a multicenter prospective cohort study.","authors":"Lin Li, Wenbin Xu, Yiqian Fang, Qian Jiang, Yanfei Zhou, Yan Chen, Qian Yang","doi":"10.1080/0886022X.2025.2455524","DOIUrl":"10.1080/0886022X.2025.2455524","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the risk factors for falls in elderly maintenance hemodialysis patients, construct a nomogram prediction model and validate the application.</p><p><strong>Background: </strong>Elderly maintenance hemodialysis patients face a high risk of falls, and there are fewer and less effective fall-specific assessment tools.</p><p><strong>Method: </strong>A total of 871 elderly hemodialysis patients from 9 hospitals in Chengdu City from October 2023 to December 2024 were selected as the study objects. Baseline characteristics and fall outcomes of patients in the fall group and non-fall group were recorded and compared through 6-month follow-up. Multivariable logistic regression analysis was employed to identify independent risk factors, and construct the nomogram prediction model and complete the internal verification of the model. 218 elderly maintenance hemodialysis patients from three other hospitals in Chengdu City were selected for a 6-month follow-up of falls from January to February 2024 to complete the external validation of the model.</p><p><strong>Result: </strong>The incidence of falls in elderly maintenance hemodialysis patients was 31.96%, and logistic regression analysis showed that age, sex, visual impairment, intradialytic hypotension, cognitive impairment and depression were independent risk factors for falls. Both internal and external validation of the model demonstrated area under the curve greater than 0.80. Furthermore, calibration plots, the Hosmer-Lemeshow test, and clinical decision curves all demonstrated that the model had good calibration and clinical utility.</p><p><strong>Conclusion: </strong>The nomogram constructed based on the above risk factors can provide scientific basis and practical tools for early clinical identification of high-risk groups of falls.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2455524"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma brain-derived neurotrophic factor before hemodialysis reduces the risk of depression in patients with chronic renal failure.","authors":"Juan Antonio Suárez-Cuenca, Nuri Perla Campos-Nolasco, Ernesto Rodríguez-Ayala, Ana Daniela Zepeda-Làmbarry, Marta Georgina Ochoa-Madrigal, Diana Maldonado-Tapia, Eduardo Vera-Gómez, Alejandro Hernández-Patricio, Gustavo Martínez-Torres, Yareni Bernal-Figueroa, Juan Antonio Pineda-Juárez, José Gutiérrez-Salinas, Christian Gabriel Toledo-Lozano, Silvia García","doi":"10.1080/0886022X.2025.2463561","DOIUrl":"10.1080/0886022X.2025.2463561","url":null,"abstract":"<p><strong>Background: </strong>Neurotrophins are related with depressive disorders. Significant neurotrophins variations occur during renal replacement therapy, but whether peri-hemodialysis availability is associated with depression in patients with Chronic Kidney Disease (CKD) is yet unclear.</p><p><strong>Aim: </strong>To determine dynamic concentrations of neurotrophins in the peri-hemodialysis range and their association with depressive symptoms in patients with CKD.</p><p><strong>Methods: </strong>Pre-, and post-hemodialysis plasma concentrations of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), as well as their plasma clearance rates, were determined (multiplexing) in patients with stage 5 CKD. Depressive symptoms, as assessed by the Beck Depression Inventory-II (BDI-II), were determined. Finally, the bioavailability of BDNF and NGF was related to the score of depressive symptoms.</p><p><strong>Results: </strong>Fifty-three patients were divided according to depressive symptoms. Pre-hemodialysis plasma BDNF was lower in patients with depressive disorder; whereas basal BDNF value >220 pg/mL independently reduced the risk for depressive disorder (Odds Ratio 0.23, <i>p</i> = 0.047) at uni- and multivariate analysis. Post-hemodialysis concentration and clearance rate of neurotrophins were not related with depressive symptoms.</p><p><strong>Conclusion: </strong>Higher plasma BDNF before hemodialysis reduces the risk of mild depression in patients with CKD under renal replacement therapy.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2463561"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China.","authors":"Sheng Li, Weiting He, Hok-Him Yau, Jianteng Xie, Yaxi Zhu, Xiaojie Chen, Shaogui Zhang, Yifan Zhang, Pengjun Liao, Hui Liu, Liwen Li, Liye Zhong, Wenjian Wang","doi":"10.1080/0886022X.2025.2453006","DOIUrl":"10.1080/0886022X.2025.2453006","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the efficacy and safety of bortezomib with thalidomide and dexamethasone (BTD) and bortezomib with cyclophosphamide and dexamethasone (BCD) as the initial treatment for renal amyloid light chain (AL) amyloidosis in Chinese cohort.</p><p><strong>Methods: </strong>A cohort of 174 patients with AL amyloidosis was studied in Guangdong Provincial People's Hospital from January 2008 to August 2023. Propensity-score matching cases were applied to assess the outcomes of patients treated with BTD and BCD regimen. Primary outcomes were patients achieving hematologic response and organ responses, and the secondary endpoints were patients progressing to end-stage renal disease or all-cause death.</p><p><strong>Results: </strong>44 Patients were included. The hematologic complete response rate (CR) in the BTD group was comparable between the groups of BTD group and BCD. However, the time to achieve hematologic CR was significantly shorter in the BTD group compared to the BCD group (4.97 vs. 7.71 mon, <i>p</i> = 0.010). Furthermore, when reaching hematologic response, the cumulative dose of bortezomib that standardized by body surface area (BSA) was lower in BTD group than in the BCD group (10.4 vs. 15.6 mg/m², <i>p</i> = 0.013). There was no significant difference of renal and cardiac response between groups. However, post-treatment proteinuria levels after treatment were significantly lower in the BTD group compared to those in the BCD group (747 mg/24h vs. 2928 mg/24h, <i>p</i> = 0.048).</p><p><strong>Conclusions: </strong>Compared to BCD regimen for renal AL amyloidosis, initial treatment with BTD regimen demonstrated similar rates of hematologic CR but showed superior reduction in proteinuria, reduced cumulative dose of bortezomib and faster time-to-response.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2453006"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triglyceride-glucose index and acute kidney injury risk in critically ill patients with coronary artery disease.","authors":"Yi Zhang, Gang Li, Junjie Li, Bohao Jian, Keke Wang, Jiantao Chen, Jian Hou, Jianbo Liao, Zhuoming Zhou, Zhongkai Wu, Mengya Liang","doi":"10.1080/0886022X.2025.2466818","DOIUrl":"10.1080/0886022X.2025.2466818","url":null,"abstract":"<p><strong>Background: </strong>The triglyceride-glucose (TyG) index, proven a reliable and simple surrogate of insulin resistance, has shown potential associations with cardiovascular outcomes and renal diseases. This research delved into the utility of the TyG index in predicting the risk of acute kidney injury (AKI) in patients with coronary artery disease (CAD), an area not extensively covered in existing literature.</p><p><strong>Methods: </strong>A cohort of patients with CAD was recruited from the Medical Information Mart for Intensive Care-IV database, and categorized into quartiles based on their TyG index. The primary outcome was AKI incidence, and the secondary outcome was renal replacement therapy (RRT). Scatterplot histograms, cox proportional hazards models, Kaplan-Meier survival curves, and restricted cubic splines were employed to investigate the association between the TyG index and the risk of AKI in patients with CAD.</p><p><strong>Results: </strong>A total of 1,501 patients were enrolled in this study, predominantly male (61.56%), with a median age of 69.80 years. The AKI incidence was 67.22% among all patients, with the AKI stages increased with higher TyG levels (<i>P</i> for trend <0.001). The Kaplan-Meier survival analyses demonstrated statistically significant differences in AKI incidence and RRT application throughout the entire cohort, stratified by the TyG index quartiles (<i>p</i> < 0.001). Additionally, the restricted cubic spline analysis revealed a non-linear association between the TyG index and the risk of AKI (<i>P</i> for non-linear =0.637). Both multivariate Cox proportional hazards analyses (HR 1.62; 95% CI 1.15-2.27; <i>p</i> = 0.005) and multivariate logistic regression analyses (OR 2.16; 95% CI 1.18-3.94; <i>p</i> = 0.012) showed that the elevated TyG index was significantly related to AKI incidence. The association between TyG index and the risk of AKI is more significant in patients without diabetes (HR 1.27; 95% CI 1.14-1.42; <i>p</i> < 0.001), compared to patients with diabetes (<i>P</i> for interaction =0.013).</p><p><strong>Conclusions: </strong>In summary, the TyG index emerged as a reliable predictor for the occurrence of AKI in CAD patients during ICU stay. Furthermore, it is also anticipated to serve as a valuable indicator for non-diabetic patients in predicting the incidence of AKI.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2466818"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study.","authors":"Jiangtao Li, Lirui Wang, Yuqiu Lu, Ying Zhou, Yue Chen","doi":"10.1080/0886022X.2025.2464830","DOIUrl":"10.1080/0886022X.2025.2464830","url":null,"abstract":"<p><strong>Introduction: </strong>For hemodialysis patients at high risk of bleeding, a regional anticoagulant can be used, such as citrate or nafamostat mesylate (NM). The objective of this study was to evaluate NM as an alternative to citrate for anticoagulation in hemodialysis patients at high risk of bleeding.</p><p><strong>Methods: </strong>This retrospective single-center study included consecutive patients in our dialysis center treated with either citrate or NM anticoagulation for hemodialysis from January 2022 to December 2023.The primary outcome was major clotting, defined as premature dialysis due to extracorporeal circuit clotting. The secondary outcome was the incidence of a major bleeding episode during or after hemodialysis.</p><p><strong>Results: </strong>In total, 651hemodialysis sessions were performed in 196 patients and were compared (289 citrate and 362 NM anticoagulation). A lower number of premature dialysis due to clotting occurred in the NM sessions compared to citrate sessions (0.84% vs.5.19%, <i>p</i> = 0.001). NM was associated with a lower risk of major clotting compared with citrate during treatment (OR:0.063; CI: 0.008-0.475; <i>p</i> = 0.007). Regarding second outcome, no more major bleeding events related to NM occurred compared to citrate.</p><p><strong>Conclusion: </strong>Among hemodialysis patients with high risk of bleeding, anticoagulation with NM, compared with citrate anticoagulation, provided relatively better efficacy, with no bleeding increment. NM is a valid alternative to citrate for hemodialysis patients at high risk of bleeding.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2464830"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significance of matrix remodeling associated 7 (MXRA7) in pathogenesis or management of renal diseases deserves more investigations.","authors":"Yiqiang Wang","doi":"10.1080/0886022X.2024.2449575","DOIUrl":"10.1080/0886022X.2024.2449575","url":null,"abstract":"","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2449575"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142953554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}